Factor V Leiden, Hormone Replacement Therapy, and Risk of Venous Thromboembolic Events in Women With Coronary Disease-Reference-Cited by-同舟云学术

Factor V Leiden, Hormone Replacement Therapy, and Risk of Venous Thromboembolic Events in Women With Coronary Disease

Published:2002-06 Issue:6 Volume:22 Page:1012-1017
ISSN:1079-5642
Container-title:Arteriosclerosis, Thrombosis, and Vascular Biology
language:en
Short-container-title:ATVB

Author:

Herrington David M.¹,Vittinghoff Eric¹,Howard Timothy D.¹,Major David A.¹,Owen John¹,Reboussin David M.¹,Bowden Donald¹,Bittner Vera¹,Simon Joel A.¹,Grady Deborah¹,Hulley Stephen B.¹

Affiliation:

1. From the Department of Internal Medicine, Sections on Cardiology (D.M.H., D.A.M.), Medical Genetics (T.D.H.), and Hematology and Oncology (J.O.), and the Departments of Public Health Sciences (D.M.R.) and Biochemistry (D.B.), Wake Forest University School of Medicine, Winston-Salem, NC; the Department of Epidemiology and Biostatistics (E.V., J.A.S., D.G., S.B.H.), University of California, San Francisco; and the Department of Medicine (V.B.), University of Alabama at Birmingham.

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Cardiology and Cardiovascular Medicine

Reference45 articles.

1. Mutation in blood coagulation factor V associated with resistance to activated protein C

2. Familial thrombophilia due to a previously unrecognized mechanism characterized by poor anticoagulant response to activated protein C: prediction of a cofactor to activated protein C.

3. Linkage between inherited resistance to activated protein C and factor V gene mutation in venous thrombosis

4. Venous thrombosis due to poor anticoagulant response to activated protein C: Leiden Thrombophilia Study

5. High risk of thrombosis in patients homozygous for factor V Leiden (activated protein C resistance) [see comments]

Cited by 133 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Exploring the potential for a set of UK hormone replacement therapy eligibility guidelines: A suggested proposal on the topic of venous thromboembolism;Post Reproductive Health;2023-12-27

2. Hormone replacement therapy in women with history of thrombosis or a thrombophilia;Post Reproductive Health;2022-12-27

3. Eligibility criteria for Menopausal Hormone Therapy (MHT): a position statement from a consortium of scientific societies for the use of MHT in women with medical conditions. MHT Eligibility Criteria Group;Maturitas;2022-12

4. Oral postmenopausal hormone therapy and genetic risk on venous thromboembolism: gene-hormone interaction results from a large prospective cohort study;Menopause;2022-01-10

5. The Interaction of Menopause and Chronic Disease;Each Woman’s Menopause: An Evidence Based Resource;2021-12-03